JP2017519028A - 重度の高トリグリセリド血症の処置 - Google Patents

重度の高トリグリセリド血症の処置 Download PDF

Info

Publication number
JP2017519028A
JP2017519028A JP2016575073A JP2016575073A JP2017519028A JP 2017519028 A JP2017519028 A JP 2017519028A JP 2016575073 A JP2016575073 A JP 2016575073A JP 2016575073 A JP2016575073 A JP 2016575073A JP 2017519028 A JP2017519028 A JP 2017519028A
Authority
JP
Japan
Prior art keywords
mbx
composition
compound
salt
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2016575073A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017519028A5 (OSRAM
Inventor
ポル・ブーズ
ヨンジュン・チェ
ロバート・エル・マーティン
チャールズ・エイ・マックウェーター
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CymaBay Therapeutics Inc
Original Assignee
CymaBay Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CymaBay Therapeutics Inc filed Critical CymaBay Therapeutics Inc
Publication of JP2017519028A publication Critical patent/JP2017519028A/ja
Publication of JP2017519028A5 publication Critical patent/JP2017519028A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
JP2016575073A 2014-06-26 2015-06-25 重度の高トリグリセリド血症の処置 Withdrawn JP2017519028A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462017444P 2014-06-26 2014-06-26
US62/017,444 2014-06-26
PCT/US2015/037596 WO2015200580A1 (en) 2014-06-26 2015-06-25 Treatment of severe hypertriglyceridemia

Publications (2)

Publication Number Publication Date
JP2017519028A true JP2017519028A (ja) 2017-07-13
JP2017519028A5 JP2017519028A5 (OSRAM) 2018-08-02

Family

ID=53511030

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016575073A Withdrawn JP2017519028A (ja) 2014-06-26 2015-06-25 重度の高トリグリセリド血症の処置

Country Status (16)

Country Link
US (1) US20150374649A1 (OSRAM)
EP (1) EP3160458A1 (OSRAM)
JP (1) JP2017519028A (OSRAM)
KR (1) KR20170020514A (OSRAM)
CN (1) CN106470675A (OSRAM)
AU (1) AU2015279905A1 (OSRAM)
BR (1) BR112016028918A2 (OSRAM)
CA (1) CA2951280A1 (OSRAM)
CL (1) CL2016003290A1 (OSRAM)
EA (1) EA201790091A1 (OSRAM)
HK (1) HK1231380A1 (OSRAM)
IL (1) IL249757A0 (OSRAM)
MX (1) MX2016017081A (OSRAM)
PH (1) PH12016502415A1 (OSRAM)
SG (1) SG11201610243YA (OSRAM)
WO (1) WO2015200580A1 (OSRAM)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
HRP20181914T1 (hr) 2014-03-20 2019-01-11 Cymabay Therapeutics, Inc. Liječenje intrahepatičnih kolestatskih bolesti
SG11201608077PA (en) 2014-04-11 2016-10-28 Cymabay Therapeutics Inc Treatment of nafld and nash
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
SG11202005850VA (en) * 2017-12-21 2020-07-29 Kowa Co Methods of treatment of hypertrigl yceridemia
US20210145775A1 (en) 2019-11-14 2021-05-20 Cymabay Therapeutics, Inc. Treatment of intestinal barrier dysfunction and associated diseases
US20210145774A1 (en) 2019-11-14 2021-05-20 Cymabay Therapeutics, Inc. Treatment of alcoholic liver disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2100877B1 (en) 2003-09-19 2012-01-25 Janssen Pharmaceutica N.V. 4-((Phenoxyalkyl)thio)-phenoxyacetic acids and analogs
JO3006B1 (ar) * 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
US9061012B2 (en) * 2010-03-30 2015-06-23 Novartis Ag Uses of DGAT1 inhibitors

Also Published As

Publication number Publication date
CA2951280A1 (en) 2015-12-30
BR112016028918A2 (pt) 2017-08-22
CN106470675A (zh) 2017-03-01
HK1231380A1 (zh) 2017-12-22
EP3160458A1 (en) 2017-05-03
KR20170020514A (ko) 2017-02-22
MX2016017081A (es) 2017-05-01
US20150374649A1 (en) 2015-12-31
AU2015279905A1 (en) 2017-02-02
SG11201610243YA (en) 2017-01-27
WO2015200580A1 (en) 2015-12-30
IL249757A0 (en) 2017-02-28
EA201790091A1 (ru) 2017-07-31
CL2016003290A1 (es) 2017-09-08
PH12016502415A1 (en) 2017-02-27

Similar Documents

Publication Publication Date Title
US11141399B2 (en) Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US6835750B1 (en) Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
US11406611B2 (en) Treatment of intrahepatic cholestatic diseases
US20150374649A1 (en) Treatment of Severe Hypertriglyceridemia
US20140004183A1 (en) Methods for treating cardiovascular disease in statin-tolerant subjects
EA011637B1 (ru) Лечение с использованием омега-3 жирных кислот и агониста и/или антагониста ppar и их комбинированный продукт
JP2015523360A (ja) 小児メタボリック症候群を治療する方法
JP7079735B2 (ja) 肝内胆汁うっ滞性疾患の処置
EP1997485A1 (en) Pharmaceutical composition comprising meglitinide for prevention of hepatic fibrosis
EP2730281B1 (en) Anti-obesity agent comprising high-purity epa
HK1229212B (en) Treatment of intrahepatic cholestatic diseases
HK1229212A1 (en) Treatment of intrahepatic cholestatic diseases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180618

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180618

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20190130